Tag Archives: entrepreneurship

Partnering Opens April 27 for RESI San Diego 

21 Apr

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Life Science Nation (LSN) is pleased to announce that partnering for RESI San Diego will officially launch on Monday, April 27.

For attendees, partnering is the most important part of the RESI experience. It is where outreach begins, meetings take shape, and the conference starts to turn into real business development activity.

With an expanding group of investors already registered and more joining every day, partnering launch gives attendees the opportunity to begin reviewing profiles, identifying targets, and requesting meetings before schedules begin to fill. The accompanying investor logo splash highlights the breadth of investor participation already confirmed for RESI San Diego and reinforces the value of acting early.

At RESI San Diego, partnering takes place across a five-day hybrid format. Attendees can begin conversations in person on June 22 at the Julep Event Venue in San Diego and continue those discussions during the virtual partnering days on June 23–24 and June 29–30. This structure gives companies more opportunities to connect, follow up, and keep momentum moving after the initial introduction.

For startups, emerging companies, service providers, and investors alike, early access to the partnering platform creates a significant advantage. Companies can strengthen profiles, build targeted outreach lists, and secure meetings with investors, strategic partners, CROs, service providers, and ecosystem organizations before the busiest weeks leading up to the conference.

Beyond partnering, RESI San Diego offers additional opportunities to build visibility and reinforce conversations started through the platform. Attendees can participate in investor panels, workshops, networking receptions, the exhibition hall, and the Innovator’s Pitch Challenge, where companies present directly to investors and receive live feedback.

To help attendees make the most of the platform, LSN will host a partnering tutorial webinar on Tuesday, April 28. The session will provide an overview of the RESI partnering system, share best practices for creating an effective profile, and offer tips for maximizing meeting opportunities before and during RESI San Diego.

Register for the partnering tutorial here: https://us02web.zoom.us/webinar/register/WN_BgTWGwKKS4mATlTZVhyoHA

Register for RESI San Diego

Tags: , , , , , , , ,

From Plan to Progress: Execution Risk 

21 Apr

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

As part of Life Science Nation’s series on converting scientific innovation into investable signal, the focus now moves to execution risk. Once a company has established market needs, demonstrated technical feasibility, and defined a regulatory path, the next question becomes whether the team can actually deliver.

Execution risks are about the company’s ability to move from strategy to progress. It includes leadership, operational discipline, hiring, partnerships, timelines, and the ability to consistently hit milestones. Even strong science and a compelling opportunity can lose credibility if a company cannot execute against its plan.

This article examines how companies build confidence through clear priorities, realistic timelines, strong teams, and the operational structure needed to keep momentum moving forward.

Execution Risk

From Plan to Progress

With market, technical, and regulatory clarity in place, the question shifts from possibility to delivery: can this actually be executed?

Execution risk reflects whether the company can translate its strategy into measurable progress. Strong science and a well-articulated plan are not enough. Investors are funding the ability to execute under real constraints.

Many companies struggle here not because they lack vision, but because they lack operational discipline. Plans remain high-level, milestones are vague, and capital is deployed without direct linkage to risk reduction.

Execution begins with the team. You need the right mix of scientific, clinical, regulatory, and operational experience for the stage you are in, and leadership that can make decisions under uncertainty. Capability matters, but so does judgment.

Milestone discipline provides structure. Progress must be broken into clear, achievable steps, where each milestone reduces a specific element of risk and moves the company toward a defined value inflection point. A 12-, 24-, and 36-month roadmap ties these milestones together and forces trade-offs.

Operational planning, resource management, and partner oversight determine whether those milestones can be met. Most life science companies depend heavily on CROs, CMOs, and other external partners; selecting and managing them is a central part of execution, not a peripheral task.

Speed and adaptability maintain momentum. Development rarely proceeds linearly. Data will force changes. The ability to adjust direction without losing focus or burning through capital is a defining feature of strong execution.

Governance and structure close the loop. Board composition, information flow, and accountability mechanisms determine how quickly issues are surfaced and addressed. Without this, even high-quality teams drift.

Execution risk is resolved when plans reliably convert into measurable progress and capital consistently turns into risk reduction rather than motion.

Core Elements of Execution Risk

  • Team capability
  • Leadership and decision making
  • Milestone discipline
  • Milestone roadmap
  • Operational plan
  • Resource management
  • External partner management
  • Speed and adaptability
  • Governance and structure

Next in the series: Economic Risk — Defining the Value Creation Opportunity

Previous Articles：

  1. Technical Risk – From Belief to Evidence
  2. The Problem Is Not the Science: A Seven-Part Series on De-Risking, Signal, and Investability
  3. From Proof to Approval: Regulatory Risk

Tags: , , , , , , , , , , , , , , , ,

Reception & Event List for Convention Week in San Diego

21 Apr

By Sougato Das, President and COO, LSN

Sougato-DasConvention week in San Diego has become much more than a single conference. One of the major events taking place during the week is RESI San Diego 2026, hosted by Life Science Nation on June 22, followed by four virtual partnering days on June 23–24 and June 29–30. This is the best place to secure meetings with early stage investors.

Around RESI and the Convention, investors, founders, pharmas, service providers, and regional delegations host receptions, networking events, investor forums, pitch sessions, private meetings, and educational programs across the city.

For attendees, the week often becomes a full schedule of opportunities that extends well beyond the official conference agenda. A company may attend RESI or Convention during the day and continue conversations at networking receptions and evening events across San Diego.

That is why having a compiled list of convention week events can be so valuable. Life Science Nation has curated a list of convention week events taking place throughout San Diego to help attendees better navigate the week. Covering Sunday, June 21 through Friday, June 26, the list serves as a useful resource for attendees looking to plan their schedules and make the most of their time in San Diego.

The list includes events for a range of audiences and interests, from investor networking and startup showcases to regional receptions, educational panels, business development gatherings, and informal social events. Some events are designed specifically for early-stage companies looking to connect with investors, while others are focused on strategic partnerships, market trends, or geographic regions.

Convention week can also be an important opportunity for companies to make the most of their time in San Diego. Rather than relying on one conference alone, attendees often use the week to build a broader schedule of meetings and introductions.

Whether attendees are focused on fundraising, partnering, business development, or networking, convention week offers a wide range of ways to connect.

View the Compiled List of Convention Week Events

Tags: , , , , , , , , , , , , , , , , , , ,

Hot Investor Mandate: Asia-Headquartered Global VC Invests Internationally in Early to Growth-Stage Opportunities in Medtech and AI-Enabled Solutions

21 Apr

The firm is a globally diversified healthcare venture capital firm headquartered in Asia, with a strong presence across North America, Europe, and other international markets. The firm maintains a globally balanced portfolio and partners with a broad network of institutional, clinical, and commercial stakeholders. In addition to capital, the firm provides hands-on support in strategy, cross-border expansion, manufacturing partnerships, and distribution, helping portfolio companies scale internationally and navigate complex healthcare ecosystems.  

The firm invests across early- to growth-stage opportunities, with a focus on medical devices, digital health, healthcare services, and AI-enabled solutions. Key areas of interest include oncology and radiotherapy, ophthalmology, brain health and neuromodulation, cardiovascular diseases, women’s and children’s health, and chronic disease management such as diabetes. The firm prioritizes technologies that address meaningful clinical needs and have the potential for broad global impact.  

From a company and management team perspective, the firm seeks to partner with mission-driven founders developing innovative healthcare solutions. The firm does not impose strict requirements on management teams but values integrity, strong execution capability, and the ability to scale across international markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: US-Based Life Sciences VC Invests in Early to Growth-Stage Therapeutics Companies With Novel Mechanisms of Action

21 Apr

 
The firm is a life sciences venture capital firm based in the United States focused on early- and growth-stage biotech and pharmaceutical companies. The firm manages substantial assets and typically makes initial investments in the low- to mid-single-digit millions, primarily through equity, with occasional use of convertible structures. The firm seeks to take meaningful ownership positions and plays an active role in the development of its portfolio companies. While the firm invests across the U.S., it has a particular interest in opportunities outside of the major biotech hubs.  

The firm focuses exclusively on therapeutic companies within the biotechnology sector. The firm is generally agnostic to modality and indication but prioritizes assets with novel mechanisms of action that address clear unmet medical needs. The firm typically invests in companies ranging from late preclinical through Phase II clinical development. The firm does not invest in diagnostics, medical devices, digital health, or healthcare IT.  

From a company and management team perspective, the firm does not impose strict requirements but typically requires board representation in connection with its investments to enable active collaboration and strategic involvement throughout company development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: Family-Office Backed Investment Firm Seeks Consumer Healthcare and Life Sciences Companies in North America and Europe

21 Apr

A family office-backed private investment firm founded in the mid-2000s maintains a global presence across North America and Europe. The firm leverages deep operating and investment experience to partner with growth-oriented companies across technology-enabled sectors. The firm deploys flexible capital through venture, growth equity, and private equity strategies, investing across stages from early-stage through later growth rounds. The firm maintains a diversified global portfolio and partners with management teams to drive scalable, long-term value creation.  

The firm invests across technology-enabled consumer and enterprise businesses, as well as healthcare and select life sciences opportunities. Areas of activity include consumer platforms, digital services, biotech, and healthcare services. The firm targets companies with defensible business models, strong competitive positioning, and the ability to scale effectively. The investment approach emphasizes long-term growth, sustainable differentiation, and cross-sector innovation.  

From a company and management team perspective, the firm partners with founders and executives who demonstrate operational excellence, clear strategic vision, and the ability to scale businesses significantly. The firm emphasizes long-term relationships and provides more than capital, offering strategic guidance, operational support, and access to an extensive network. The firm invests through both equity and structured transactions and works collaboratively with leadership teams to support commercialization, product expansion, and organizational growth across global markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: Biotech Company Makes Strategic Investments Across Medical Devices, Diagnostics, and Digital Health Technologies Addressing Longevity 

21 Apr

The firm is a healthcare technology company developing and commercializing AI-powered, laboratory-based diagnostics for early detection and prevention of cancer and chronic diseases. Following a recent financing event tied to public market activity, the firm is allocating a portion of capital toward strategic investments and potential acquisitions. The firm is particularly interested in identifying companies that could serve as future acquisition targets, with a focus on those generating early revenues.  

The firm is actively evaluating opportunities across diagnostics, digital health, and medical devices that address chronic disease detection, longevity, and nutrition-based interventions. Areas of particular interest include solutions that advance “food-as-medicine” approaches and technologies that support prevention and long-term health optimization.  

From a company and management team perspective, the firm does not impose strict requirements but prioritizes companies with demonstrated commercial traction and solutions aligned with its broader platform and strategic roadmap. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

← Older Entries